

Designing clinical trials using causal models



Tom Snelling, Yue Wu, Charlie McLeod, Andre Schultz, Steven Mascaro, Owen Woodberry ABNMS 2022

Some facts about cystic fibrosis





1 in 4 people with a CF-related lung exacerbation will not return to their previous lung function



The average person will be admitted to hospital once per year to manage a lung exacerbation



Separation of evidence creation and decision-making



Figure 1 Dynamic relationship between evidence review and synthesis and evidence-based decision making.

https://en.wikipedia.org/wiki/Scientific_method

Teutsch; MedDesMak 2005

Designing studies that are reactive to decision-making



Figure 1 Dynamic relationship between evidence review and synthesis and evidence-based decision making.

https://en.wikipedia.org/wiki/Scientific_method

Teutsch; MedDesMak 2005





Clinical problem/ question



1. Stating the clinical question

Broadly, what (and whose) clinical **decision/ action** do we wish to inform?

- How **should** pulmonary exacerbations of CF be managed?
- Which antibiotics? What dose? What frequency? What duration? What route of administration should be prescribed?
- When **should/can** inhaled antibiotics be used? At what dose, frequency and duration?
- Which adjunctive therapies **should** be used?
- How **should** chest physiotherapy be delivered?



Clinical problem/ question

Causal model









































Infection

.

Clinical problem/ question

Causal model

3. Define the Estimand: PICO + EP

ICH GCP E9 (R1):

Estimand = target of estimation (what) \rightarrow statistical **estimator** (how)

P: Population(target)

I: Intervention

C: <u>C</u>omparator

O: <u>O</u>utcome/ Endpoint

E: Effect measure (eg risk ratio, average difference)

P: Post-assignment events (death, missing data, loss to follow-up, nonadherence, treatment cross-over)

3. Estimand: Population (target)

3. Estimand: Intervention (prescribe vs take)

3. Define the estimand: Outcome

3. Define the estimand: Endpoints

3. Define the estimand: intent-to-treat effect

3. Define the estimand: per-protocol effect

Key messages

- Managing CF is complicated (and probably complex)
 - Our trials need to be as simple as possible, but no simpler
- Trials should test alternative *actions*, not *hypotheses*.
- To know how we *should* act, we need to anticipate their potential consequences.
- To do this we *must* have a causal model of the clinical problem
- Causal models, motivated by clinical decision problems, can help us clarify our estimands and design more useful trials.

